Eikon Therapeutics, Inc. - Common Stock (EIKN)
Stock listed on Nasdaq Stock Market (NASDAQ) · Biological Products, (No Diagnostic Substances) · prices in USD
Price
6.39 USD+0.84 (+15.14%)Close on (end-of-day, stored)
Key statistics · as of Nov 4, 2026
- 52-week range
- 5.01 – 17.40
- Market cap
- 346.1M USD
- P/E
- —
- P/B
- 0.7
- EV/EBITDA
- —
- Dividend yield
- —
- 1-year return
- —
- 3-month return
- −30.6%
- Volatility (1y)
- —
- Max drawdown (1y)
- —
- Beta (1y)
- —
- RSI (14)
- 44
- Revenue growth
- —
- ROE
- —
- ROIC
- —
- Debt / equity
- —
Ratios are calculated by AlphaScope from stored prices and reported financial statements; see the methodology. Blank values mean the data is not available.
Peers · Biological Products, (No Diagnostic Substances)
| Company | Market cap | 1-year return |
|---|---|---|
| Amgen Inc. - Common Stock (AMGN) | 251.9B | +64.1% |
| Gilead Sciences, Inc. - Common Stock (GILD) | 211.2B | +47.4% |
| Moderna, Inc. - Common Stock (MRNA) | 88.5B | +797.7% |
| Revolution Medicines, Inc. - Common Stock (RVMD) | 40.3B | +219.6% |
| Biogen Inc. - Common Stock (BIIB) | 36.8B | +61.4% |
| Exelixis, Inc. - Common Stock (EXEL) | 18B | +91.1% |
| Neurocrine Biosciences, Inc. - Common Stock (NBIX) | 14.9B | +5.9% |
| Halozyme Therapeutics, Inc. - Common Stock (HALO) | 14.6B | +99.5% |